Method for treating mucositis, method for treating tumor, and pharmaceutical combination

Abstract

Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I): to the subject in need thereof. The application also discloses a method for treating damages, especially gastrointestinal damages including mucositis such as stomatitis induced by an anti-tumor agent, wherein the method comprises administering a fatty acid derivative of formula (I) to the subject who is receiving the anti-tumor agent.

What is claimed is: 
     
         1 . A method for treating mucositis in a mammalian subject, which comprises administering a pharmaceutically effective amount of (−)-7-[(2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydro-cyclopenta[b]pyran-5-yl]heptanoic acid or its functional derivative to the subject in need thereof. 
     
     
         2 . The method as described in  claim 1 , wherein the mucositis is stomatitis. 
     
     
         3 . The method as described in  claim 1 , wherein the mucositis is oral mucositis. 
     
     
         4 . The method as described in  claim 1 , wherein the subject is receiving an anti-tumor agent that is selected from the group consisting of an alkylating agent, an antimetabolite, an antibiotic, a plant alkaloid, a molecular targeting drug, a hormone, a platinum complex, an antisense, an antibody and RNAi, wherein the molecular targeting drug is selected from the group consisting of imatinib, gefinitib, erlotinib, sorafenib, sunitinib, trastuzumab, rituximab, gemtuzumab-ozogamicin, bevacizumab and cetuximab, the hormone is selected from group consisting of prednisolone, diethylstilbestrol and tamoxifen, the antisense is selected from the group consisting of bcl-2 antisense, hsp27 antisense, XIAP antisense, PKC-alpha antisense and hypoxia-induced factor antisense, the antibody is selected from the group consisting of CD20 antibody, Her2 antibody, VEGF antibody and EGFR antibody, and the RNAi is RNAi targeted Ribonucleotide reductase. 
     
     
         5 . The method as described in  claim 4 , wherein said anti-tumor agent is 5-FU or tegafur. 
     
     
         6 . The method as described in  claim 4 , wherein said anti-tumor agent is cisplatin. 
     
     
         7 . The method as described in  claim 4 , wherein the anti-tumor agent is selected from the group consisting of an alkylating agent, an antimetabolite, an antibiotic and a plant alkaloid. 
     
     
         8 . The method as described in  claim 4 , wherein the mucositis is induced by the antitumor agent.